Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy

Biochem Biophys Res Commun. 2017 Jul 22;489(2):103-108. doi: 10.1016/j.bbrc.2017.05.097. Epub 2017 May 19.

Abstract

Chemotherapy is still the main adjuvant strategy in the treatment of cancer, however, chemoresistance is also frequently encountered. Autophagy inhibition has been widely accepted as a promising therapeutic strategy in cancer, while the lack of effective and specific autophagy inhibitors hinders its application. Here we found that dichloroacetate (DCA), a small molecule compound, could significantly inhibit the autophagy induced by Doxorubicin in breast cancer cells. And DCA markedly enhances Doxorubicin-induced breast cancer cell death and anti-proliferation in vitro. But the sensitization to Dox of DCA was significantly reduced through induction of autophagy by rapamycin. Moreover, the combined therapy of Dox and DCA could significantly inhibit tumor growth in vivo and prolong mouse survival time. Taken together, we demonstrate that DCA could inhibit doxorubicin-inducing autophagy and provide a novel strategy for improving the anti-cancer efficacy of chemotherapy.

Keywords: Autophagy; Breast cancer; Chemotherapy; Dichloroacetate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Autophagy / drug effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Dichloroacetic Acid / pharmacology*
  • Dose-Response Relationship, Drug
  • Doxorubicin / antagonists & inhibitors
  • Doxorubicin / pharmacology
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Paclitaxel / pharmacology*
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Dichloroacetic Acid
  • Paclitaxel